Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:applicationStatus |
fully approved in some regions
|
| gptkbp:approves |
gptkb:FDA
EMA |
| gptkbp:brand |
Comirnaty
|
| gptkbp:clinicalTrials |
Phase 3
44,000 |
| gptkbp:coatOfArms |
two doses required for full vaccination
|
| gptkbp:collaborations |
Pfizer_and_BioNTech
|
| gptkbp:community |
significant
|
| gptkbp:communityOutreach |
community engagement efforts
|
| gptkbp:communityPartnerships |
partnerships with governments
|
| gptkbp:contraindication |
fatigue
headache muscle pain fever chills |
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:BioNTech |
| gptkbp:diseaseResistance |
cold chain logistics
public information campaigns published in peer-reviewed journals reduces transmission |
| gptkbp:distribution |
global
|
| gptkbp:dosageForm |
two doses
|
| gptkbp:emergencyServices |
gptkb:European_Union
gptkb:United_States |
| gptkbp:endOfProduction |
under study
|
| gptkbp:evaluates |
95% in clinical trials
|
| gptkbp:expansion |
Yes
|
| gptkbp:firstAppearance |
December 11, 2020
|
| gptkbp:foughtAgainst |
Reduced efficacy against some variants
|
| gptkbp:hasAccessTo |
available in many countries
|
| gptkbp:hasAuthorityOver |
December 2020
|
| gptkbp:hasResearchInterest |
successful in trials
|
| gptkbp:healthcare |
reduced hospitalizations
|
| gptkbp:historicalResearch |
international collaboration
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pfizer-BioNTech vaccine
|
| gptkbp:incubationPeriod |
fast-tracked due to pandemic
|
| gptkbp:isConsidered |
Yes
|
| gptkbp:isIncorporatedIn |
high efficacy against severe disease
|
| gptkbp:muzzleVelocity |
reduced mortality rates
|
| gptkbp:notable_player |
generally positive
government and private funding ongoing safety monitoring viral vector vaccine mass vaccination campaigns approved by multiple agencies concerns about side effects high effectiveness against severe disease |
| gptkbp:produces |
gptkb:Germany
gptkb:United_States |
| gptkbp:providesGuidelinesFor |
recommended by health authorities
|
| gptkbp:providesSupportFor |
gptkb:COVAX
various countries |
| gptkbp:researchContribution |
distributed worldwide
|
| gptkbp:researchInterest |
gptkb:Lancet
|
| gptkbp:safetyFeatures |
gptkb:VAERS
|
| gptkbp:storage |
-70 degrees Celsius
|
| gptkbp:systemRequirements |
requires ultra-cold storage
|
| gptkbp:takesPlaceIn |
complex supply chain
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
mRNA vaccine
|